Sodium Butyrate Improves Renal Injury in Diabetic Nephropathy Through AMPK/SIRT1/PGC-1α Signaling Pathway

Overview

Journal Sci Rep

Specialty Science

Date 2024 Aug 1

PMID 39090182

Authors

Kaili Ye

Yanling Zhao

Wen Huang

Yonglin Zhu

Affiliations

Soon will be listed here.

Abstract

Diabetic nephropathy (DN) is a prototypical chronic energy metabolism imbalance disease. The AMPK/Sirt1/PGC-1α signaling pathway plays a pivotal role in regulating energy metabolism throughout the body. Gut microbiota ferment indigestible carbohydrates to produce a variety of metabolites, particularly short-chain fatty acids (SCFAs), which exert positive effects on energy metabolism. However, the potential for SCFAs to ameliorate DN-associated renal injury via the AMPK/Sirt1/PGC-1α pathway remains a matter of debate. In this study, we investigated the effects of sodium butyrate (NaB), a SCFA, on energy metabolism in mice with spontaneous DN at two different doses. Body weight, blood glucose and lipid levels, urinary protein excretion, liver and kidney function, interleukin-6 (IL-6) levels, and the expressions of AMPK, phosphorylated AMPK (p-AMPK), mitofusin 2 (MFN2), optic atrophy 1 (OPA1), and glucagon-like peptide-1 receptor (GLP-1R) were monitored in mice. Additionally, butyrate levels, gut microbiota composition, and diversity in colonic stool were also assessed. Our findings demonstrate that exogenous NaB supplementation can improve hyperglycemia and albuminuria, reduce renal tissue inflammation, inhibit extracellular matrix accumulation and glomerular hypertrophy, and could alter the gut microbiota composition in DN. Furthermore, NaB was found to upregulate the expressions of MFN2, OPA1, p-AMPK, and GLP-1R in DN renal tissue. These results suggest that NaB could improve the composition of gut microbiota in DN, activate the AMPK/Sirt1/PGC-1α signaling pathway, and enhance mitochondrial function to regulate energy metabolism throughout the body. Collectively, our findings indicate that NaB may be a novel therapeutic agent for the treatment of DN.

Citing Articles

Beneficial Effects of Butyrate on Kidney Disease.

Diep T, Liu H, Yan L Nutrients. 2025; 17(5).

PMID: 40077642 PMC: 11901450. DOI: 10.3390/nu17050772.

Machine-learning assisted discovery unveils novel interplay between gut microbiota and host metabolic disturbance in diabetic kidney disease.

Wu I, Liao Y, Tsai T, Lin C, Shen Z, Chan Y Gut Microbes. 2025; 17(1):2473506.

PMID: 40050256 PMC: 11901534. DOI: 10.1080/19490976.2025.2473506.

Sodium butyrate ameliorates mitochondrial oxidative stress and alterations in membrane-bound enzyme activities in pentylenetetrazole-induced kindling rat model.

Adebayo O, Luro G, Akeju I, Onu C, Fawehinmi M, Aderemi V Metab Brain Dis. 2025; 40(2):120.

PMID: 39913006 DOI: 10.1007/s11011-025-01550-9.

Sirtuin1 Suppresses Calcium Oxalate Nephropathy via Inhibition of Renal Proximal Tubular Cell Ferroptosis Through PGC-1α-mediated Transcriptional Coactivation.

Duan C, Li B, Liu H, Zhang Y, Yao X, Liu K Adv Sci (Weinh). 2024; 11(48):e2408945.

PMID: 39498889 PMC: 11672264. DOI: 10.1002/advs.202408945.

References

Tang X, Sun Y, Li Y, Ma S, Zhang K, Chen A . Sodium butyrate protects against oxidative stress in high-fat-diet-induced obese rats by promoting GSK-3β/Nrf2 signaling pathway and mitochondrial function. J Food Biochem. 2022; 46(10):e14334. DOI: 10.1111/jfbc.14334. View

Kang H, Ahn S, Choi P, Ko Y, Han S, Chinga F . Defective fatty acid oxidation in renal tubular epithelial cells has a key role in kidney fibrosis development. Nat Med. 2014; 21(1):37-46. PMC: 4444078. DOI: 10.1038/nm.3762. View

He M, Shi B . Gut microbiota as a potential target of metabolic syndrome: the role of probiotics and prebiotics. Cell Biosci. 2017; 7:54. PMC: 5655955. DOI: 10.1186/s13578-017-0183-1. View

Barrios C, Beaumont M, Pallister T, Villar J, Goodrich J, Clark A . Gut-Microbiota-Metabolite Axis in Early Renal Function Decline. PLoS One. 2015; 10(8):e0134311. PMC: 4524635. DOI: 10.1371/journal.pone.0134311. View

Huang W, Man Y, Gao C, Zhou L, Gu J, Xu H . Short-Chain Fatty Acids Ameliorate Diabetic Nephropathy via GPR43-Mediated Inhibition of Oxidative Stress and NF-B Signaling. Oxid Med Cell Longev. 2020; 2020:4074832. PMC: 7422068. DOI: 10.1155/2020/4074832. View

Victor P, Umapathy D, George L, Juttada U, Ganesh G, Amin K . Crosstalk between endoplasmic reticulum stress and oxidative stress in the progression of diabetic nephropathy. Cell Stress Chaperones. 2020; 26(2):311-321. PMC: 7925747. DOI: 10.1007/s12192-020-01176-z. View

Zheng Y, Ley S, Hu F . Global aetiology and epidemiology of type 2 diabetes mellitus and its complications. Nat Rev Endocrinol. 2017; 14(2):88-98. DOI: 10.1038/nrendo.2017.151. View

Zhu L, Qin S, Zhai S, Gao Y, Li L . Inulin with different degrees of polymerization modulates composition of intestinal microbiota in mice. FEMS Microbiol Lett. 2017; 364(10). DOI: 10.1093/femsle/fnx075. View

Vrieze A, van Nood E, Holleman F, Salojarvi J, Kootte R, Bartelsman J . Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome. Gastroenterology. 2012; 143(4):913-6.e7. DOI: 10.1053/j.gastro.2012.06.031. View

10.

Fernandes R, Viana S, Nunes S, Reis F . Diabetic gut microbiota dysbiosis as an inflammaging and immunosenescence condition that fosters progression of retinopathy and nephropathy. Biochim Biophys Acta Mol Basis Dis. 2018; 1865(7):1876-1897. DOI: 10.1016/j.bbadis.2018.09.032. View

11.

Zhang P, Li L, Han X, Li Q, Zhang X, Liu J . Fecal microbiota transplantation improves metabolism and gut microbiome composition in db/db mice. Acta Pharmacol Sin. 2020; 41(5):678-685. PMC: 7468362. DOI: 10.1038/s41401-019-0330-9. View

12.

Tang C, Ahmed K, Gille A, Lu S, Grone H, Tunaru S . Loss of FFA2 and FFA3 increases insulin secretion and improves glucose tolerance in type 2 diabetes. Nat Med. 2015; 21(2):173-7. DOI: 10.1038/nm.3779. View

13.

Sabatino A, Regolisti G, Cosola C, Gesualdo L, Fiaccadori E . Intestinal Microbiota in Type 2 Diabetes and Chronic Kidney Disease. Curr Diab Rep. 2017; 17(3):16. DOI: 10.1007/s11892-017-0841-z. View

14.

Dong W, Jia Y, Liu X, Zhang H, Li T, Huang W . Sodium butyrate activates NRF2 to ameliorate diabetic nephropathy possibly via inhibition of HDAC. J Endocrinol. 2016; 232(1):71-83. DOI: 10.1530/JOE-16-0322. View

15.

Yapa N, Lisnyak V, Reljic B, Ryan M . Mitochondrial dynamics in health and disease. FEBS Lett. 2021; 595(8):1184-1204. DOI: 10.1002/1873-3468.14077. View

16.

Ren X, Liu G, Wang Y, Zhang W, Xue F, Li R . Influence of Dipeptidyl Peptidase-IV Inhibitor Sitagliptin on Extracellular Signal-Regulated Kinases 1/2 Signaling in Rats with Diabetic Nephropathy. Pharmacology. 2017; 100(1-2):1-13. DOI: 10.1159/000455874. View

17.

Saeedi P, Petersohn I, Salpea P, Malanda B, Karuranga S, Unwin N . Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9 edition. Diabetes Res Clin Pract. 2019; 157:107843. DOI: 10.1016/j.diabres.2019.107843. View

18.

Huang W, Guo H, Deng X, Zhu T, Xiong J, Xu Y . Short-Chain Fatty Acids Inhibit Oxidative Stress and Inflammation in Mesangial Cells Induced by High Glucose and Lipopolysaccharide. Exp Clin Endocrinol Diabetes. 2017; 125(2):98-105. DOI: 10.1055/s-0042-121493. View

19.

Drucker D . Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1. Cell Metab. 2018; 27(4):740-756. DOI: 10.1016/j.cmet.2018.03.001. View

20.

Morrison D, Preston T . Formation of short chain fatty acids by the gut microbiota and their impact on human metabolism. Gut Microbes. 2016; 7(3):189-200. PMC: 4939913. DOI: 10.1080/19490976.2015.1134082. View